Development Level

Tbio 32 | 10,625
Tchem 13 | 1,890

IMPC Phenotype

preweaning lethality, complete... 6 | 633
decreased bone mineral content 2 | 157
decreased lean body mass 2 | 195
decreased total body fat amoun... 2 | 186
embryonic lethality prior to o... 2 | 148
abnormal QRS complex 1 | 25
abnormal bone mineralization 1 | 55
abnormal coping response 1 | 12
abnormal heart left ventricle ... 1 | 20
abnormal kidney morphology 1 | 30
cardiovascular system phenotyp... 1 | 35
decreased IgM level 1 | 1
decreased body length 1 | 108
decreased body weight 1 | 174
decreased bone mineral density 1 | 126
decreased circulating HDL chol... 1 | 77
decreased circulating alanine ... 1 | 53
decreased circulating alkaline... 1 | 41
decreased circulating calcium ... 1 | 33
decreased lactate dehydrogenas... 1 | 14
embryonic lethality prior to t... 1 | 187
increased bone mineral content 1 | 92
increased circulating alkaline... 1 | 119
increased circulating choleste... 1 | 53
increased circulating free fat... 1 | 17
increased circulating sodium l... 1 | 71
increased exploration in new e... 1 | 56
increased or absent threshold ... 1 | 128
preweaning lethality, incomple... 1 | 260

Disease

ovarian cancer 29 | 8,491
osteosarcoma 23 | 7,933
psoriasis 21 | 6,685
pancreatic ductal adenocarcinoma liver metastasis 18 | 1,795
Multiple myeloma 17 | 1,327
lung cancer 17 | 4,473
glioblastoma 16 | 5,572
medulloblastoma, large-cell 15 | 6,234
Cancer 13 | 2,346
pancreatic cancer 13 | 2,300
intraductal papillary-mucinous neoplasm (IPMN) 12 | 3,289
lung adenocarcinoma 12 | 2,714
Breast cancer 11 | 3,098
malignant mesothelioma 11 | 3,163
Waldenstrons macroglobulinemia 10 | 764
intraductal papillary-mucinous carcinoma (IPMC) 10 | 2,988
non-small cell lung cancer 10 | 2,798
Liver carcinoma 9 | 217
atypical teratoid / rhabdoid tumor 9 | 4,369
invasive ductal carcinoma 9 | 2,950
primitive neuroectodermal tumor 9 | 3,031
intraductal papillary-mucinous adenoma (IPMA) 8 | 2,956
Pick disease 7 | 1,893
acute quadriplegic myopathy 7 | 1,157
adrenocortical carcinoma 7 | 1,427
adult high grade glioma 7 | 2,148
astrocytic glioma 7 | 2,241
astrocytoma 7 | 1,493
diabetes mellitus 7 | 1,663
Degenerative polyarthritis 6 | 93
Hypoglycemia 6 | 81
breast carcinoma 6 | 1,614
colon cancer 6 | 1,475
dermatomyositis 6 | 966
ductal carcinoma in situ 6 | 1,745
ependymoma 6 | 2,514
group 3 medulloblastoma 6 | 2,254
group 4 medulloblastoma 6 | 1,875
pilocytic astrocytoma 6 | 3,086
primary pancreatic ductal adenocarcinoma 6 | 1,271
subependymal giant cell astrocytoma 6 | 2,287
tuberculosis 6 | 1,563
ulcerative colitis 6 | 2,087
Lactic acidosis 5 | 43
Leigh disease 5 | 81
Neoplastic Syndromes, Hereditary 5 | 48
Obesity 5 | 616
Osteoporosis 5 | 259
Persistent generalized lymphadenopathy 5 | 15
Phaeochromocytoma 5 | 20
Stomach Neoplasms 5 | 282
atypical teratoid/rhabdoid tumor 5 | 1,095
lung carcinoma 5 | 2,844
oligodendroglioma 5 | 2,849
Anoxia 4 | 33
Congenital hemolytic anemia 4 | 31
Down syndrome 4 | 548
Drug-Induced Liver Injury 4 | 118
Gastrointestinal stromal tumor 4 | 61
Glycogen storage disease 4 | 37
Hemangioma 4 | 35
Neoplasm Invasiveness 4 | 127
Neurofibromatosis 4 | 37
Paraganglioma 4 | 12
Pyruvate decarboxylase deficiency 4 | 15
aldosterone-producing adenoma 4 | 664
medulloblastoma 4 | 1,524
pediatric high grade glioma 4 | 2,712
pituitary cancer 4 | 1,972
posterior fossa group A ependymoma 4 | 1,511
sonic hedgehog group medulloblastoma 4 | 1,482
Animal Mammary Neoplasms 3 | 135
Carney Triad 3 | 3
Chondroma 3 | 12
Cowden disease 3 | 20
Disease Progression 3 | 125
Gastrointestinal Stromal Tumors 3 | 8
Hamartoma Syndrome, Multiple 3 | 9
Heart disease 3 | 279
Hyperinsulinism 3 | 63
Mammary Neoplasms 3 | 410
Mammary Neoplasms, Experimental 3 | 149
Mitochondrial complex II deficiency 3 | 5
Myocardial Ischemia 3 | 169
Myoglobinuria 3 | 11
Neurodegenerative disease 3 | 383
Paraganglioma and gastric stromal sarcoma 3 | 3
Renal Cell Carcinoma 3 | 199
Rheumatoid Arthritis 3 | 1,170
extra-adrenal pheochromocytoma 3 | 7
hereditary spastic paraplegia 3 | 313
interstitial cystitis 3 | 2,299
non primary Sjogren syndrome sicca 3 | 840
pancreatic carcinoma 3 | 567
Endometriosis 2 | 535
autosomal dominant Emery-Dreifuss muscular dystrophy 2 | 499
esophageal adenocarcinoma 2 | 737
hepatocellular carcinoma 2 | 550
nasopharyngeal carcinoma 2 | 1,056
nephrosclerosis 2 | 329

Tissue

Blood and immune system 45 | 17,994
Cardiovascular System 45 | 17,957
Digestive Tract 45 | 18,472
Endocrine System 45 | 18,511
Female tissues 45 | 18,646
Liver and Pancreas 45 | 18,135
Male tissues 45 | 17,968
Nervous System 45 | 18,560
Skin and soft tissues 45 | 18,114
Urinary Tract 45 | 18,443
Respiratory system 44 | 17,483

Target Family

Enzyme 36 | 4,146
Kinase 5 | 634
Transporter 3 | 473
Non-IDG 1 | 11,969

PathwayCommons: smpdb Pathway

Warburg Effect 45 | 45
Phenytoin (Antiarrhythmic) Act... 79 | 79
Lidocaine (Antiarrhythmic) Act... 61 | 61
Carvedilol Action Pathway 60 | 60
Labetalol Action Pathway 60 | 60
Muscle/Heart Contraction 60 | 60
Acebutolol Action Pathway 59 | 59
Alprenolol Action Pathway 59 | 59
Amiodarone Action Pathway 59 | 59
Amlodipine Action Pathway 59 | 59
Arbutamine Action Pathway 59 | 59
Atenolol Action Pathway 59 | 59
Betaxolol Action Pathway 59 | 59
Bevantolol Action Pathway 59 | 59
Bisoprolol Action Pathway 59 | 59
Bopindolol Action Pathway 59 | 59
Bupranolol Action Pathway 59 | 59
Carteolol Action Pathway 59 | 59
Diltiazem Action Pathway 59 | 59
Disopyramide Action Pathway 59 | 59
Dobutamine Action Pathway 59 | 59
Epinephrine Action Pathway 59 | 59
Esmolol Action Pathway 59 | 59
Felodipine Action Pathway 59 | 59
Flecainide Action Pathway 59 | 59
Fosphenytoin (Antiarrhythmic) ... 59 | 59
Ibutilide Action Pathway 59 | 59
Isoprenaline Action Pathway 59 | 59
Isradipine Action Pathway 59 | 59
Levobunolol Action Pathway 59 | 59
Metipranolol Action Pathway 59 | 59
Metoprolol Action Pathway 59 | 59
Mexiletine Action Pathway 59 | 59
Nadolol Action Pathway 59 | 59
Nebivolol Action Pathway 59 | 59
Nifedipine Action Pathway 59 | 59
Nimodipine Action Pathway 59 | 59
Nisoldipine Action Pathway 59 | 59
Nitrendipine Action Pathway 59 | 59
Oxprenolol Action Pathway 59 | 59
Penbutolol Action Pathway 59 | 59
Pindolol Action Pathway 59 | 59
Practolol Action Pathway 59 | 59
Procainamide (Antiarrhythmic) ... 59 | 59
Propranolol Action Pathway 59 | 59
Quinidine Action Pathway 59 | 59
Sotalol Action Pathway 59 | 59
Timolol Action Pathway 59 | 59
Tocainide Action Pathway 59 | 59
Verapamil Action Pathway 59 | 59
Azathioprine Action Pathway 47 | 47
Ibuprofen Action Pathway 47 | 47
Mercaptopurine Action Pathway 47 | 47
Thioguanine Action Pathway 47 | 47
Intracellular Signalling Throu... 38 | 38
AICA-Ribosiduria 37 | 37
Adenine phosphoribosyltransfer... 37 | 37
Adenosine Deaminase Deficiency 37 | 37
Adenylosuccinate Lyase Deficie... 37 | 37
Gout or Kelley-Seegmiller Synd... 37 | 37
Intracellular Signalling Throu... 37 | 37
Lesch-Nyhan Syndrome (LNS) 37 | 37
Mitochondrial DNA depletion sy... 37 | 37
Molybdenum Cofactor Deficiency 37 | 37
Myoadenylate deaminase deficie... 37 | 37
Purine Metabolism 37 | 37
Purine Nucleoside Phosphorylas... 37 | 37
Xanthine Dehydrogenase Deficie... 37 | 37
Xanthinuria type I 37 | 37
Xanthinuria type II 37 | 37
Fc Epsilon Receptor I Signalin... 36 | 36
Morphine Action Pathway 35 | 35
Retinol Metabolism 35 | 35
Vitamin A Deficiency 35 | 35
Celecoxib Action Pathway 34 | 34
Eplerenone Action Pathway 33 | 33
Spironolactone Action Pathway 33 | 33
Amiloride Action Pathway 32 | 32
Bendroflumethiazide Action Pat... 32 | 32
Blue diaper syndrome 32 | 32
Bumetanide Action Pathway 32 | 32
Chlorothiazide Action Pathway 32 | 32
Chlorthalidone Action Pathway 32 | 32
Cyclothiazide Action Pathway 32 | 32
Cystinuria 32 | 32
Ethacrynic Acid Action Pathway 32 | 32
Furosemide Action Pathway 32 | 32
Glucose Transporter Defect (SG... 32 | 32
Hartnup Disorder 32 | 32
Hydrochlorothiazide Action Pat... 32 | 32
Hydroflumethiazide Action Path... 32 | 32
Iminoglycinuria 32 | 32
Indapamide Action Pathway 32 | 32
Kidney Function 32 | 32
Lysinuric Protein Intolerance 32 | 32
Lysinuric protein intolerance ... 32 | 32
Methyclothiazide Action Pathwa... 32 | 32
Metolazone Action Pathway 32 | 32
Polythiazide Action Pathway 32 | 32
Quinethazone Action Pathway 32 | 32

This is where graphics are reside..
Name Gene Development Level Target Family Log Novelty  Pubmed Score  Antibody Count  Knowledge Availability 
Phosphoglycerate mutase 2 PGAM2 Tbio Enzyme -1.54638 36.2 160
6-phosphogluconate dehydrogenase, decarboxylating PGD Tchem Enzyme -2.55417 348.6 173
Monocarboxylate transporter 1 SLC16A1 Tchem Transporter -2.42636 263.7 235
Hexokinase-2 HK2 Tchem Kinase -2.60415 391.1 373
6-phosphogluconolactonase PGLS Tbio Enzyme -2.23905 159.7 136
Neutral amino acid transporter B(0) SLC1A5 Tbio Transporter -2.55051 323.7 122
Fumarate hydratase, mitochondrial FH Tbio Enzyme -2.38028 230.7 307
Citrate synthase, mitochondrial CS Tbio Enzyme -2.59718 316.0 182
Pyruvate carboxylase, mitochondrial PC Tbio Enzyme -2.56120 349.9 207
Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex, mitochondrial DLST Tbio Enzyme -1.75775 38.4 112